Aelian Biotechnology combines CRISPR screening with single-cell sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens. Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions of drugs.

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically modified cells and then applies them in research and clinical applications that advance human health.Horizon builds human disease models and reagents derived from genetically-engineered cells that its customers use, or that are deployed on their behalf to: gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted at these genetic drivers; and develop companion diagnostics that predict patient response in the clinic. In this way they apply genetic knowledge to provide biological insights that translate to improved research and development outcomes for drug developers and treatment regimens that better serve patients.Horizon has an international customer base of over 1,400 unique organisations across more than 50 countries, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Group supplies its products and services into a range of markets, estimated to be worth over £29 billion in 2015.Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.

Horizon Genomics provides the largest collection of validated human knock-out cell lines thereby empowering biomedical research. It employs a powerful functional genomics platform based on haploid genetics in human cell lines. Horizon Genomics is constructing next generation haploid genetics tools for internal target discovery programs and as part of its commitment to support experimental human genetics in the wider scientific community. In addition, Horizon Genomics offers partnerships to perform haploid genetic screens for drug target discovery and to elucidate drug mechanism of action.

Haplogen GmbH is a privately held biotechnology company with an entirely novel target identification technology based on human haploid genetics and a drug discovery pipeline in infectious diseases. Haplogen’s mission is to exploit human haploid genetics to improve human health.

Laboratory of Prof. Dr. Giulio Superti-Furga